That definitely is just market opportunity. Here's the
That definitely is just market opportunity. Here's the crazy part. Todos doesn't even need it to be successful
Given all the stuff that was approved or that people want to use...
- remdesivir, ivermectin, hydroxychloroquine, chloroquine, monoclonal antibody treatments – bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab)
That once worked, never worked, sorta works sometimes, it shows the market demand for just about anything that has a story attached to it, as people unfortunately are desperate.
I imagine once the story gets out about Tollovid, that it actually worked in two different studies and you can actually buy it today, the market might go nuts for Tollovid.
I can imagine sales potentially doubling each month for Tollovid. I'm sure Todos is thinking it. We'll see what happens. Then add into that what Gerald mentioned of Tollovid being the base and that they can add other things to. Also the potential for Tollovid one day being over the counter like Zicam or other pills. I posted Zicam sold in 2020 for over half a billion.
The positive data from this small trial today with the hardest setting (hospitalized) is a marketing gold mine for Tollovid. Everyone I know that I suggested taking Tollovid, I want back today and said, see the news today.
Now a question for Todos would be, how many bottles can you produce in 2022 and what are the margins. We know the margins of testing today which was great to hear.
Can they product 100M bottles?
100M @ $50 = $5B
But lets take 1M bottles that should be easily doable
1M @ $50 = Todos Market Cap
That isn't even the Max and that doesn't include any of the other revenue
The challenge for Todos is, they have so many avenues to go down, which ones to you pick first. I guess it depends on expansion of compassionate use and emergency use approval in a few countries. Each use/approval will have a greater acceleration of Tollovid sales in my view but what do I know. I'm the guy that bought at the HOD and close to LOD today.
1
Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...
Continue Reading
Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...
Continue Reading
They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...
Continue Reading
Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...
Continue Reading
They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...
Continue Reading
Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...
Continue Reading
Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...
Continue Reading
Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...
Continue Reading
A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...
Continue Reading
Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...
Continue Reading
Top 5 Most Recently Viewed Articles
Anticipating Financial Results from Revolution Medicines Revolution Medicines, Inc. (Nasdaq: RVMD), an innovative clinical oncology company, has officially announced an upcoming report on its financial results for the first quarter of 2025. This highly anticipated release is scheduled for May 7, 2025, following market close, and will be followed by a detailed discussion...
Continue Reading
Air Canada's Operational Challenges and Responses Air Canada has recently faced significant operational hurdles due to severe winter weather and an aircraft incident impacting its Toronto Pearson international hub. These challenges have necessitated a comprehensive update from the airline about its current status and ongoing recovery efforts. Recent Weather Impact on...
Continue Reading
Scott Korn Steps into the Film Industry In a bold move that marks a new chapter in his career, Scott Korn, the founder and CEO of The Korn Group, has officially stepped into the world of film production with the action-thriller Tin Soldier. This exciting development showcases his ambition and dedication to exploring creative avenues beyond his established domain of...
Continue Reading
KE Holdings Inc. Financial Performance Overview KE Holdings Inc. (NYSE: BEKE), commonly referred to as Beike, a prominent platform that integrates online and offline housing transactions, has released its unaudited financial results for the third quarter of 2025. This report outlines the company's operational efficiency, technology advancement, and strategic growth amidst...
Continue Reading
University of Maryland Introduces Innovative Finance Lab The Ed Snider Center for Enterprise and Markets at the University of Maryland's Robert H. Smith School of Business has recently taken a significant step in research with the launch of its Social Media and Market Dynamics (SMMD) Lab. This initiative is set to explore the intricate relationship between social media...
Continue Reading